Abbott cuts another 199 COVID test-making jobs

Today's Big News

May 24, 2023

FDA needs more time for Sarepta's DMD gene therapy—spurring a deja vu of Exondys 51


The clock's ticking on Stelara: Amgen, J&J ink patent settlement


Abbott cuts another 199 jobs at Maine COVID test-making site


Mirati's long wait for next lung cancer med ends in phase 3 failure


Viatris scouts for new board chair as longtime leader Coury transitions to advisory role


Bayer's acting BD chief lobbies for the job the only way he knows how: by making deals

 

Featured

UPDATE: FDA needs more time for Sarepta's DMD gene therapy—spurring a deja vu of Exondys 51

The FDA needs a wee bit more time to consider the approval of Sarepta’s gene therapy for Duchenne muscular dystrophy, however the agency has indicated an accelerated approval is likely in a restricted age group.
12-14
Jun
San Diego, CA
 

Top Stories

The clock's ticking on Stelara: Amgen, J&J ink patent settlement

After the recent high-profile loss of exclusivity for AbbVie's megablockbuster immunology drug Humira, industry watchers' eyes moved to Johnson & Johnson's Stelara as one of the next major drugs expected to face biosimilar competition. Tuesday, the industry got more information about when exactly that clash might occur.

Abbott cuts another 199 jobs at Maine COVID test-making site

As Abbott shaves down its COVID-related revenue forecasts, so too is the company whittling down its COVID test-making workforce.

Mirati's long wait for next lung cancer med ends in phase 3 failure

After a five and a half month wait, Mirati Therapeutics finally has the answer it’s been waiting for on a lung cancer med called sitravatinib. The therapy didn't work.

Viatris scouts for new board chair as longtime leader Robert Coury transitions to advisory role

Viatris Chairman Robert Coury has called the shots at Mylan and its successor Viatris for many years, but now he's getting ready to hang it up. 

Bayer's acting BD chief lobbies for the job the only way he knows how: by making deals

Friedemann Janus, Ph.D., may, as of now, only be leading Bayer’s business development team on an acting basis, but he'd like to lose the "interim" to his title.

Innoviva subsidiary Entasis scores FDA nod for bacterial pneumonia combo drug Xacduro

Innoviva subsidiary Entasis has captured an FDA approval for Xacduro, a treatment for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Xacduro targets bacteria known as Acinetobacter baumannii, a pathogen that can cause infections in the blood, urinary tract and lungs (pneumonia).

Annexon's eye disease med improved vision in a phase 2 trial but flunked the primary goal. The CEO was thrilled

Annexon's geographic atrophy treatment failed to improve lesion growth in a phase 2 trial but did improve vision, which the CEO thinks will support a late-stage study.

Cepheid taps former Philips North America head Vitor Rocha as president

As it transitions away from COVID-19 tests, shifting its focus back toward a range of other molecular diagnostics, Cepheid is also making some changes to its corporate makeup.

FDA clears Braeburn's long-acting Brixadi to treat opioid use disorder

Right after approving a new overdose reversal therapy, the FDA gave Braeburn's long-acting Brixadi an endorsement to treat opioid use disorder.

ElevateBio takes fundraising crown with $401M series D, adds Novo Nordisk to growing army of partners

Move over, ReNAgade. ElevateBio’s $401 million haul has already knocked the RNA company’s $300 million series A off the fundraising top spot after just one day.
 
Fierce podcasts

Don't miss an episode

'The Top Line': 2023's biopharma layoffs, plus the headlines

This week on "The Top Line," we''ll discuss the recent biopharma layoff trends, plus Elizabeth Holmes, Sarepta Therapeutics, Abbott's FDA approval, and the rest of the week's headlines.

 

Resources

Whitepaper

ChatGPT in Drug Discovery: Rise of Large Language Models

ChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations.
Whitepaper

Discovering High-Affinity, Functional Anti-GLP-1R Antibodies

Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties.
eBook

Decentralized Clinical Trials: The Complete Guide for 2023

Discover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success.
Research

How Lilly’s Legal and Library Services Empower Teams Across the Drug Development Pipeline

What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how.
Whitepaper

Medical Affairs Metamorphosis VI: The Changing Face of Stakeholder Engagement

This paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing.
Research

Maximizing Clinical Trial Success

Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies
Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
 

Industry Events

 

Upcoming Fierce Events

12-14
Jun
San Diego, CA
13
Jun
Free Virtual Event
20-22
Jun
Free Virtual Event
22
Jun
Free Virtual Event
18-19
Jul
July 18-19, 2023 | Jersey City, NJ

View all events